Clinical Trials

712 enrolled 14 charts

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT03155620 2026-04-14

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1,377 enrolled 10 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT06351371 2026-04-14

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Other solid neoplasm

Malignant Solid Neoplasm

NCT01038778 2026-04-13

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

47 enrolled 15 charts

Genitourinary

Carcinoma, Renal Cell

NCT01575548 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

129 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell

NCT01841736 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

171 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT02143414 2026-04-13

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

53 enrolled 12 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

34 enrolled 18 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02392429 2026-04-13

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Other hematologic neoplasm

87 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02968810 2026-04-13

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

52 enrolled 15 charts

Fibrosis, Carcinoma, Hepatocellular

NCT03348631 2026-04-13

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

62 enrolled 14 charts

Gynecologic

Ovarian Neoplasms

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

17 enrolled 14 charts

Clinical Stage III Gastric Cancer AJCC v8

NCT03831932 2026-04-13

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 2 FDA

Lymphoid

Hodgkin Disease

NCT03914300 2026-04-13

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2/3 Active not recruiting

11 enrolled 11 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03952585 2026-04-13

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

384 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

12 enrolled 25 charts

Thoracic

Lung Neoplasms

NCT04345913 2026-04-13

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

24 enrolled 24 charts

Breast

Triple Negative Breast Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT05490771 2026-04-13

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Lymphoma, Multiple Myeloma

NCT06308822 2026-04-13

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma

NCT06390839 2026-04-13

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

43 enrolled 10 charts

Lymphoid

Lymphoma

NCT06400238 2026-04-13

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Lymphoma, Multiple Myeloma

NCT06400251 2026-04-13

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Lymphoma, Multiple Myeloma

NCT03878095 2026-04-08

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

24 enrolled 12 charts

Cholangiocarcinoma

NCT06385483 2026-04-07

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06390826 2026-04-07

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

10 enrolled 10 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Lymphoma, Multiple Myeloma

NCT03213678 2026-04-02

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

18 enrolled 12 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03504644 2026-04-02

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

40 enrolled 18 charts

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03210714 2026-04-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)